CD3+CD4+T细胞和CD3+CD8+T细胞水平与晚期非小细胞肺癌患者预后的关系

doi:10.3969/j.issn.1671-7171.2020.01.010

Abstract
Figure/Table
References (12)
Related Citation (15)

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】To study the relationship between the levels of CD3⁺CD4⁺T cells and CD3⁺CD8⁺T cells and the prognosis of patients with advanced non-small cell lung cancer(NSCLC).【Methods】 One hundred and eighty patients with advanced NSCLC cancer were treated in our hospital. All patients received PG chemotherapy (Pemetrexed + Nedaplatin) for 2 cycles.Peripheral venous blood samples of patients after chemotherapy were collected, and the levels of T lymphocyte subsets (CD3⁺CD4⁺, CD3⁺CD8⁺) were determined . Multivariate logistic regression analysis was used to analyze the independent influencing factors of patients' short-term prognosis and to observe the relationship between the levels of CD3⁺CD4⁺, CD3⁺CD8⁺ and patients' short-term prognosis. 【Results】 After two chemotherapy cycles of 180 patients, 43 cases (23.89%) of PR and 116 cases (64.44%) of SD were found and were included in the disease control group, while 21 cases (11.67%) of PD were included in the disease uncontrolled group; the proportion of KPS score ≥ 80, tumor diameter ≥ 5cm, low differentiation, TNM stage IV, platelet count ≥ 300×10⁹/L in the disease control group were significantly lower than those in the disease uncontrol group (P<0.05); the levels of CD3⁺CD4⁺, CD3⁺CD8⁺ were significantly higher than those of the disease uncontrol group (P<0.05). Multivariate logistic regression analysis revealed that KPS score, tumor diameter, degree of differentiation, TNM stage and extra-platelet count were independent influencing factors for the recent prognosis of patients with advanced NSCLC (P<0.05), whereas CD3⁺CD4⁺, CD3⁺CD8⁺ levels were not independent influencing factors for the recent prognosis of patients (P>0.05).【Conclusion】The recent efficacy of chemotherapy for advanced NSCLC cancer is not significantly correlated with CD3⁺CD4⁺, CD3⁺CD8⁺ levels, suggesting that detection of peripheral blood t lymphocyte subsets could not serve as a basis for judging the efficacy of chemotherapy.

Key words： T lymphocyte subsets Carcinoma,non-small-cell lung Prognosis

Received: 26 August 2019

PACS:

R730.26

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2020.01.010 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2020/V37/I1/29

[1] Jaemin J,Hyun KS,Jung KY,et al. Efficacy of pemetrexed-based chemotherapy in comparison to non-pemetrexed-based chemotherapy in advanced, ALK+ non-small cell lung cancer[J]. Yons Med J, 2018, 59(2):202-205.
[2] 唐金明, 李旭, 谢李,等. ⅢA(N2)期非小细胞肺癌的诊疗进展[J]. 医学临床研究, 2015, 32(12):2414-2422.
[3] 龙博雨. PD-1/PD-L1信号通路在非小细胞肺癌免疫微环境和治疗方面的研究进展[J]. 实用癌症杂志, 2018, 194(5):173-175.
[4] 吴姗姗, 严峰, 邓玉玲,等. 小细胞和非小细胞肺癌晚期患者 CD3⁺CD4⁺及CD3⁺CD8⁺T淋巴细胞亚群的差异[J]. 中国免疫学杂志, 2015, 31(1):114-116.
[5] 中国抗癌协会肺癌专业委员会. 2010中国肺癌临床指南[M]. 北京:人民卫生出版社, 2010:7.
[6] 中华人民共和国卫生部. 中国常见恶性肿瘤诊治规范[M]. 北京医科大学、中国协和医科大学联合出版社, 1991:25-29.
[7] 姜红波.培美曲塞联合顺铂治疗非小细胞肺癌的临床疗效评价[J].中国现代药物应用,2019,13(1):96-97.
[8] Tanino R,Tsubata Y,Harashima N , et al. Novel drug-resistance mechanisms of pemetrexed-treated non-small cell lung cancer[J]. Oncotarget, 2018, 9(24):168-170.
[9] 孔倩, 王心悦, 蒋日成, 等. 不同二线方案治疗178例晚期非小细胞肺癌的预后及影响因素[J]. 中华肿瘤杂志, 2016, 38(4):294-299.
[10] Liang H, Chu X, Zhao J, et al. Elevated peripheral blood B lymphocytes and CD3⁺CD4-CD8- T lymphocytes in patients with non-small cell lung cancer: A preliminary study on peripheral immune profile[J]. Oncol Lett, 2018, 15(6):8387-8395.
[11] 刘东利, 张宇祥, 杜延玲. 老年非小细胞肺癌患者中外周血T细胞的表达与癌胚抗原表达的相关性[J]. 中国实验诊断学, 2017, 21(8):1329-1332.
[12] 李小雪, 王鑫, 姚舒洋,等. T淋巴细胞亚群水平在晚期肺腺癌治疗中的变化及其临床意义[J]. 肿瘤研究与临床, 2017, 29(7):457-459.